Literature DB >> 20572015

Aberrant epigenetic silencing of tumor suppressor genes is reversed by direct reprogramming.

Shulamit Ron-Bigger1, Ori Bar-Nur, Sara Isaac, Michael Bocker, Frank Lyko, Amir Eden.   

Abstract

Direct reprogramming procedures reset the epigenetic memory of cells and convert differentiated somatic cells into pluripotent stem cells. In addition to epigenetic memory of cell identity, which is established during development, somatic cells can accumulate abnormal epigenetic changes that can contribute to pathological conditions. Aberrant promoter hypermethylation and epigenetic silencing of tumor suppressor genes (TSGs) are now recognized as an important mechanism in tumor initiation and progression. Here, we have studied the fate of the silenced TSGs p16(CDKN2A) during direct reprogramming. We find that following reprogramming, p16 expression is restored and is stably maintained even when cells are induced to differentiate. Large-scale methylation profiling of donor cells identified aberrant methylation at hundreds of additional sites. Methylation at many, but not all these sites was reversed following reprogramming. Our results suggest that reprogramming approaches may be applied to repair the epigenetic lesions associated with cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20572015     DOI: 10.1002/stem.468

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  15 in total

1.  Human-induced pluripotent stem cells as a source of hepatocyte-like cells: new kids on the block.

Authors:  C Busletta; E Novo; M Parola
Journal:  Hepatol Int       Date:  2011-07-23       Impact factor: 6.047

Review 2.  The tumorigenicity of human embryonic and induced pluripotent stem cells.

Authors:  Uri Ben-David; Nissim Benvenisty
Journal:  Nat Rev Cancer       Date:  2011-03-10       Impact factor: 60.716

Review 3.  DNA methylation and cellular reprogramming.

Authors:  Daniel D De Carvalho; Jueng Soo You; Peter A Jones
Journal:  Trends Cell Biol       Date:  2010-08-31       Impact factor: 20.808

4.  Aberrant DNA methyltransferase 1 expression in clear cell renal cell carcinoma development and progression.

Authors:  Ming Li; Ying Wang; Yongsheng Song; Renge Bu; Bo Yin; Xiang Fei; Qizhen Guo; Bin Wu
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

Review 5.  Epigenetic aberrations in human pluripotent stem cells.

Authors:  Shiran Bar; Nissim Benvenisty
Journal:  EMBO J       Date:  2019-05-14       Impact factor: 11.598

Review 6.  Current status in cancer cell reprogramming and its clinical implications.

Authors:  Kenan Izgi; Halit Canatan; Banu Iskender
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

7.  Synergism between DNA methylation and macroH2A1 occupancy in epigenetic silencing of the tumor suppressor gene p16(CDKN2A).

Authors:  Michal Barzily-Rokni; Nathalie Friedman; Shulamit Ron-Bigger; Sara Isaac; Dan Michlin; Amir Eden
Journal:  Nucleic Acids Res       Date:  2010-10-28       Impact factor: 16.971

8.  Reprogramming bladder cancer cells for studying cancer initiation and progression.

Authors:  Banu Iskender; Kenan Izgi; Halit Canatan
Journal:  Tumour Biol       Date:  2016-07-25

9.  Transcriptional coexpression network reveals the involvement of varying stem cell features with different dysregulations in different gastric cancer subtypes.

Authors:  Kalaivani Kalamohan; Jayaprakash Periasamy; Divya Bhaskar Rao; Georgina D Barnabas; Srigayatri Ponnaiyan; Kumaresan Ganesan
Journal:  Mol Oncol       Date:  2014-05-09       Impact factor: 6.603

10.  Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner.

Authors:  Stefan H Stricker; Andrew Feber; Pär G Engström; Helena Carén; Kathreena M Kurian; Yasuhiro Takashima; Colin Watts; Michael Way; Peter Dirks; Paul Bertone; Austin Smith; Stephan Beck; Steven M Pollard
Journal:  Genes Dev       Date:  2013-03-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.